NCT02461849 2022-06-15
Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy
Samsung Medical Center
Phase 2 Unknown
Clinical Trials
7 trialsNCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT01089595 2017-03-15
Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Fox Chase Cancer Center
Phase 2 Terminated
NCT00611689 2013-02-04
Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors
SCRI Development Innovations, LLC
Phase 1 Completed
NCT00026169 2013-01-10
Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure
National Cancer Institute (NCI)
Phase 1 Completed
NCT01271166 2011-01-06
GlivecĀ® Plus m-FOLFOX AvastinĀ® in Advanced Colorectal Cancer
Novartis
Phase 1 Terminated
NCT00180830 2006-09-11
Glivec Phase II Pediatric Study
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated